Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge
about
Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 proteinThe Structure of the Poxvirus A33 Protein Reveals a Dimer of Unique C-Type Lectin-Like DomainsPotent Neutralization of Vaccinia Virus by Divergent Murine Antibodies Targeting a Common Site of Vulnerability in L1 ProteinVaccinia virus L2 protein associates with the endoplasmic reticulum near the growing edge of crescent precursors of immature virions and stabilizes a subset of viral membrane proteinsThe mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy.Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infectionNew classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens.Kinetics and intracellular location of intramolecular disulfide bond formation mediated by the cytoplasmic redox system encoded by vaccinia virus.Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000.A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in miceAntibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors.Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 proteinThe membrane fusion step of vaccinia virus entry is cooperatively mediated by multiple viral proteins and host cell componentsEpitope mapping by random peptide phage display reveals essential residues for vaccinia extracellular enveloped virion spread.Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections.Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies.Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus.Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.Capturing the natural diversity of the human antibody response against vaccinia virusProtective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function.The Vaccinia virus complement control protein modulates adaptive immune responses during infectionSmallpox vaccines: targets of protective immunity.Interactions of the vaccinia virus A19 proteinHuman T-cell responses to vaccinia virus envelope proteins.An epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodiesPassive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organsParainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer.Characterization of a large, proteolytically processed cowpox virus membrane glycoprotein conserved in most chordopoxvirusesDevelopment of a Genus-Specific Antigen Capture ELISA for Orthopoxviruses - Target Selection and Optimized ScreeningMajor neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection modelAdjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challengesA single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses.Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001.
P2860
Q27647102-EE493E54-0FF2-4C7C-AF84-B664F8146C01Q27658759-1EADC489-50F0-4149-90DF-C43070059C36Q27684713-FB016893-02E3-45CE-AAC0-6BA29631929CQ28743094-55AEC830-7EAB-466E-9A00-C3C940D28E4CQ30223108-0CAA435F-0ABC-470F-80CC-106F964CE135Q33302672-B4779B39-9A63-493C-ABC5-85F551B6BD70Q33508318-C2989926-5AC6-40A3-A6F3-A5962C00E71FQ33664851-12073FD8-E019-4779-B731-C05B68D84EF4Q33725635-E4A8E905-ACE7-46C9-91F9-B7D93263DC96Q33743444-9660F82A-09DF-4272-867F-AED480D4E97BQ33905188-0556985D-0BDF-4B55-A74A-8C59091FC395Q33936717-1F46F515-6869-4120-8FBB-CBF5A8102017Q33967713-255C60F6-C97C-4100-B893-7792E1890C95Q34039477-8B1922C1-1DBE-4DBE-9B01-658464FCA92EQ34109783-E239D5B5-683D-4C33-8E56-D893B1073573Q34420319-4F30E993-B036-480F-B496-9DA2AF890F49Q34447009-B1F6C824-0051-40B2-816C-24ED070BFB1AQ34469836-13D7AB60-8033-428B-B2BE-189A2BC98741Q34470311-555DDFA0-5CE2-4A6F-97EB-A7C2AF916FCCQ34478724-DA8253CE-F464-40C1-891B-993D75018F92Q34502997-08343BC8-C301-4FA5-AF7C-2097E18ACB76Q34529713-DC2F5193-CC28-467B-8237-2ED91C87677DQ34716960-72FE3BDC-166D-4F70-BE90-7D2A5CEE0601Q34742926-DA3D9647-357A-4044-A57B-3D6AD9D98553Q34780607-F71C1AD2-A927-4471-8B8E-73ED5FFCB8B5Q34864699-27466C34-B960-42D3-B5C7-9C6587961158Q35101531-8103A4EB-00FC-4090-8273-AF710AB769DEQ35186318-1D60C050-8AA7-4E09-BEE8-C63DBFA70E9CQ35192889-CFCF11FE-BF47-4B37-B7F3-3C20ECE46C04Q35226200-69F2B4AF-7D44-4A5E-BC23-EE5AFF0C2A9BQ35339702-D6928A13-2241-4CC8-AB8F-9597DEC54143Q35760869-B6DEC648-FC73-44FA-B683-2A97CDB561AAQ35893584-0AF587ED-222D-4C39-A29B-4F808242E81DQ35941208-E8459CFD-F2E6-4099-8D52-982410AD1C4CQ35947572-CA1DB051-321A-493A-B158-90596B4D365CQ35948047-1327D1FC-9971-43D7-87C0-6630DE8D0021Q35951545-A21FE4BC-D1C9-4DFA-8455-879F1E9FCA60Q36130201-4DC5EA8C-FDB9-44A9-90DA-995AE5E5CA27Q36379337-E6334339-6F6C-406B-8E33-B78B4CB23CCBQ36486818-95B608AD-F3E3-426C-A048-CA761201A976
P2860
Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Combinations of polyclonal or ...... a lethal respiratory challenge
@ast
Combinations of polyclonal or ...... a lethal respiratory challenge
@en
Combinations of polyclonal or ...... a lethal respiratory challenge
@nl
type
label
Combinations of polyclonal or ...... a lethal respiratory challenge
@ast
Combinations of polyclonal or ...... a lethal respiratory challenge
@en
Combinations of polyclonal or ...... a lethal respiratory challenge
@nl
prefLabel
Combinations of polyclonal or ...... a lethal respiratory challenge
@ast
Combinations of polyclonal or ...... a lethal respiratory challenge
@en
Combinations of polyclonal or ...... a lethal respiratory challenge
@nl
P2093
P2860
P1433
P1476
Combinations of polyclonal or ...... a lethal respiratory challenge
@en
P2093
Christiana Fogg
Gary H Cohen
J Charles Whitbeck
Shlomo Lustig
P2860
P304
13454-13462
P356
10.1128/JVI.79.21.13454-13462.2005
P407
P577
2005-11-01T00:00:00Z